Novavax Inc (NVAX)vsVertex Pharmaceuticals Inc (VRTX)
NVAX
Novavax Inc
$9.42
+1.29%
HEALTHCARE · Cap: $1.62B
VRTX
Vertex Pharmaceuticals Inc
$519.51
+0.79%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2942% more annual revenue ($12.59B vs $413.80M). VRTX leads profitability with a 35.0% profit margin vs -59.9%. NVAX appears more attractively valued with a PEG of 1.32. VRTX earns a higher WallStSmart Score of 64/100 (C+).
NVAX
Avoid28
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NVAX.
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$519.51
$443.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Smaller company, higher risk/reward
ROE of -898.0% — below average capital efficiency
Revenue declined 76.3%
Earnings declined 38.1%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVAX
The strongest argument for NVAX centers on Debt/Equity. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : NVAX
The primary concerns for NVAX are Market Cap, Return on Equity, Revenue Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
NVAX profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
NVAX carries more volatility with a beta of 2.45 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 28/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novavax Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?